OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes. The company is evaluating OHR-102 eye drops in various Phase II studies for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, proliferative diabetic retinopathy, and diabetic macular edema. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. The company is headquartered in New York, New York.
Interphase Corporation, an information and communications technology company, provides connectivity, interworking, and packet processing solutions in the Pacific Rim, North America, and Europe. The company's network connectivity products include T1/E1 communication controllers that primarily support SS7 signaling, OC-3/STM-1 asynchronous transfer mode network interface cards (NICs), and Ethernet NICs; interworking products comprise OC-3/STM-1 interworking modules, and broadband access gateway and media converters; and multi-core packet processors consist of Gigabit Ethernet (GigE) and 10 GigE packet processors. It also provides penveu, a handheld device primarily for the education market that adds interactivity to the installed base of projectors and large screen displays, making any flat surface, from pull down screens to HDTVs, an interactive display system. In addition, the company offers engineering design services, such as specifications gathering; program management; electrical, mechanical, and thermal design; wireless services design for cellular, WiFi, Bluetooth, and other services; mechanical enclosure design; software design for drivers and applications; application software porting and integration; rapid prototyping; and manufacturability and testability design, product design verification testing, product certification, and production test development. Further, it offers electronics manufacturing services comprising supply chain management, custom branding and control, production assembly, integration, testing and delivery, and inventory management and logistics services. The company sells its products and services to telecom equipment and server manufacturers, as well as to the electronics industry through its direct sales force, manufacturers' representatives, value-added distributors, and Web and social media tools. Interphase Corporation was founded in 1974 and is headquartered in Carrollton, Texas.
MRV Communications, Inc. provides communications solutions to telecommunications service providers, enterprises, and governments worldwide. It operates in two segments, Network Equipment and Network Integration. The Network Equipment segment offers packet and optical solutions that enable access, aggregation, transport, and management of various communications traffic for fixed line, cable, content delivery, cloud-based, and mobile communications networks leveraging direct and channel sales through third party channel partners. This segment also develops optical edge solutions that combine packet and optical technologies, and network management software; infrastructure management solutions; and fiber optic modules for the fiber-optic communication industry. The Network Integration segment offers end-to-end solutions, including consulting, installation, and support and managed services for fixed line, cable, and mobile communications networks; and supplies a range of communications equipment, as well as provides telecommunications solutions consisting of network infrastructure, unified communications, mobility and wireless, network security, cloud computing services, managed call center services, network integration, and optimization serving the Italian market. MRV Communications, Inc. markets and sells its products through direct sales force, manufacturers' representatives, value-added-resellers, distributors, and systems integrators. The company was formerly known as MRV Technologies, Inc. and changed its name to MRV Communications, Inc. in April 1992. MRV Communications, Inc. was founded in 1988 and is headquartered in Chatsworth, California.
NeoStem, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.
Echelon Corporation develops and markets energy control networking platforms. Its products enable everyday devices, including air conditioners, appliances, electricity meters, light switches, thermostats, and valves to be inter-connected. The company's building automation product portfolio include twisted-pair smart transceivers that can be embedded into building automation devices; embedded control and communications software; wired and wireless evaluation kits; SmartServer controller, a system manager and field controller for building networks and smart-energy applications; LonWorks control network software (LNS) and OpenLNS operating system development and integration tools that allows building owners to change service providers; and third party energy management or analytics software and applications. Its outdoor lighting product portfolio comprise power-line smart transceivers to embed into outdoor light ballasts, drivers, and generators; outdoor lighting controllers; motion sensors to turn outdoor lighting fixtures on and off based on motion; Smartserver controllers and gateways for connecting outdoor lighting segments to a service center; PL/RF Bridge to connect segments of outdoor lights to a SmartServer; wireless and Ethernet gateways to access network for setup functions, administration, and communications in the system; and management software and third-party system software to manage outdoor lighting network. It operates in the Americas; Europe, the Middle East, and Africa; and the Asia Pacific and Japan. The company markets its products and services to original equipment manufacturers and systems integrators in the building, industrial, transportation, utility/home, and other automation markets through direct sales organization, third-party electronics representatives, value-added resellers, and distributors. Echelon Corporation was founded in 1988 and is headquartered in San Jose, California.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.
Midway Gold Corp. engages in the acquisition, exploration, and development of gold and silver mineral properties in North America. The company holds interest in the Pan and Gold Rock Projects located along the prolific Battle Mountain/Eureka gold trend; the Spring Valley property, which is located in the Spring Valley Mining District, Pershing County, Nevada. It also has interest in the Tonopah property, which is located in Nye County, Nevada; and the Golden Eagle property located in the Eureka mining district in Ferry County, Washington. The company was formerly known as Red Emerald Resource Corp. and changed its name to Midway Gold Corp. in July 2002. Midway Gold Corp. was founded in 1996 and is headquartered in Englewood, Colorado.
Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs. The company's principal product candidate is MRX-6, a topical cream that is in Phase 2 clinical trial for the treatment of atopic dermatitis. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis, post-operative inflammation, and/or dry eye; CFX-1 to treat cystic fibrosis; and OAX-1 for the treatment of osteoarthritis and other inflammatory diseases. The company was formerly known as Morria Biopharmaceuticals Plc and changed its name to Celsus Therapeutics Plc in June 2013. Celsus Therapeutics Plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; Janssen Pharmaceuticals; and L'Oreal. The company was founded in 2007 and is headquartered in San Diego, California.